Tenon Oncologie Médicale - APHP
Welcome,         Profile    Billing    Logout  
 4 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gligorov, Joseph
InTTercePT, NCT05041842 / 2020-005735-79: Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

Active, not recruiting
2
53
Europe
Tucatinib, Pertuzumab, Perjeta®, Trastuzumab, Herceptin® or Biosimilar, Hormone therapy, Pertuzumab/ Trastuzumab, Phesgo®
UNICANCER, Seagen Inc., ARCAGY/ GINECO GROUP
Metastatic Breast Cancer With a Isolated Brain Progression
04/25
04/26
DEMETER, NCT05932667: Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

Terminated
2
1
Europe
Milademetan, Fulvestrant, Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)
Institut Curie, Rain Oncology Inc
Advanced or Metastatic Breast Cancer
11/23
11/23
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

Terminated
2
139
Europe, RoW
Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1
Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie
HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
11/24
11/24
CUPCAKE, NCT06225505: Early Detection of Triple Negative Breast Cancer Relapse

Not yet recruiting
N/A
450
Europe
ctDNA monitoring, 68Ga-FAPI-46-PET-CT
Institut Curie, National Research Agency, France, Roche Pharma AG
Triple Negative Breast Cancer
12/26
12/28
QT-RIBRATING, NCT05623397: A Deep Learning Method to Evaluate QT on Ribociclib

Recruiting
N/A
70
Europe
Acquisition of a digitized ECG by four modalities within 20 minutes
CMC Ambroise Paré
Breast Cancer, Ribociclib
05/26
09/26
CHACRY-1501, NCT02871167: Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation

Active, not recruiting
N/A
140
Europe
Controlled ovarian hyperstimulation (COH), Oocyte/embryo freezing
Centre Oscar Lambret, University Hospital, Lille, National Cancer Institute, France, University Hospital, Montpellier
Breast Cancer
12/24
12/25
REPARP, NCT05378204: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Recruiting
N/A
120
Europe
Main study:, Sub-study:
Institut Claudius Regaud, Artios Pharma Ltd
Breast Cancer
01/27
06/27
BrainStorm, NCT04109131: A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours

Recruiting
N/A
600
Europe
Samples collection: Plasma, Blood for plasma preparation, Samples collection: CSF, CSF sample, Samples collection: Non-CNS Metastatic Tumour Tissue, Non-CNS Metastatic Tumour Tissue collection, Brain MRI, Samples collection: Serum, Blood for serum preparation
Jules Bordet Institute, La Fondation contre le cancer, Belgique, Les Amis de l'Institut Bordet, Bristol-Myers Squibb, Fondation Cancer, Luxembourg
CNS Metastases
01/28
01/29
ICRG0101, NCT04273542: Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening

Active, not recruiting
N/A
1100
Europe
liquid biopsy
Centre Jean Perrin, International Cancer Research Group, Institut Max Planck d'optique quantique
Breast Cancer Female, BRCA1 Mutation, BRCA2 Mutation
05/29
05/29

Download Options